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Inhibition of the Host Translation Shutoff Response by Herpes
Simplex Virus 1 Triggers Nuclear Envelope-Derived Autophagy
Kerstin Radtke,a Luc English,a Christiane Rondeau,a David Leib,b Roger Lippé,a Michel Desjardinsa
Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, Québec, Canadaa; Department of Microbiology and Immunology, Dartmouth Medical
School, Lebanon, New Hampshire, USAb
Macroautophagy is a cellular pathway that degrades intracellular pathogens and contributes to antigen presentation. Herpes
simplex virus 1 (HSV-1) infection triggers both macroautophagy and an additional form of autophagy that uses the nuclear en-
velope as a source of membrane. The present study constitutes the first in-depth analysis of nuclear envelope-derived autophagy
(NEDA).We established LC3a as a marker that allowed us to distinguish between NEDA andmacroautophagy in both immuno-
fluorescence and flow cytometry. NEDAwas observed in many different cell types, indicating that it is a general response to
HSV-1 infection. This autophagic pathway is known to depend on the viral protein 34.5, which can inhibit macroautophagy via
binding to beclin-1. Using mutant viruses, we were able to show that binding of beclin-1 by 34.5 had no effect on NEDA, dem-
onstrating that NEDA is regulated differently thanmacroautophagy. Instead, NEDAwas triggered in response to 34.5 binding
to protein phosphatase 1, an interaction used by the virus to prevent host cells from shutting off protein translation. NEDAwas
not triggered when late viral protein production was inhibited with acyclovir or hippuristanol, indicating that the accumulation
of these proteins might stress infected cells. Interestingly, expression of the late viral protein gH was sufficient to rescue NEDA in
the context of infection with a virus that otherwise does not support strong late viral protein expression.We argue that NEDA is
a cellular stress response triggered late during HSV-1 infection andmight compensate for the viral alteration of the macroau-
tophagic response.
Macroautophagy, the mechanism by which cells literally eatsome of their own components, plays an essential role in cell
homeostasis and nutrient recycling (1, 2). This process involves
the de novo formation of a vesicle that engulfs cytosolic protein
aggregates or organelles. To this end, a two-layered membrane
cup forms around cytoplasmic cargo. This cup expands and closes
into a vesicle, the autophagosome, which can then fuse with lyso-
somes or early endosomes for degradation of its content. The ini-
tiation of autophagosome formation requires the protein beclin-1
(3), while membrane extension is driven by two ubiquitin-like
protein conjugation systems, one of which includes LC3b. The
accumulation of membrane-bound LC3b as punctate patterns
representing autophagic vesicles is a well-established hallmark of
macroautophagy (4).
In addition to nutrient recycling, macroautophagy also serves
as a defense mechanism against intracellular pathogens like vi-
ruses (5, 6). Macroautophagosomes can directly engulf pathogens
in the cytosol and promote their degradation. This process is re-
ferred to as xenophagy. Furthermore, recent evidence shows that
macroautophagy stimulates the presentation of intracellular viral
antigens on major histocompatibility complexes I and II (7, 8),
thus alerting the adaptive branch of the immune system to help
clear the viral infection. Herpes simplex virus 1 (HSV-1) triggers
macroautophagy very early in infection, prior to the production of
viral proteins (9, 10). Later in infection, HSV-1 can inhibit both
macroautophagosome formation and fusion ofmacroautophago-
somes with lysosomes (11, 12).
Recently, we discovered a novel form of autophagy that in-
volves vesicle formation at the nuclear envelope during HSV-1
infection in mouse macrophages (13). This process is character-
ized by the formation of 4-membrane-layered LC3b-positive
structures made by coiling of the inner and outer nuclear mem-
brane and is referred to here as nuclear envelope-derived au-
tophagy (NEDA). We have shown that the 34.5 viral protein is
required for the induction of this autophagic pathway, as an
HSV-1 mutant lacking this molecule is unable to induce NEDA.
Other than the requirement of 34.5, the molecular mechanisms
governing NEDA were unknown.
The HSV-1 protein 34.5 has multiple functions. It can inter-
fere with macroautophagy induction by binding beclin-1 (12).
Second, 34.5 promotes translation of viral proteins by counter-
acting cellular translational shutoff, an antiviral defense mecha-
nism. This translational shutoff is mediated by phosphorylation
and inactivation of the  subunit of eukaryotic initiation factor 2
(eIF2). HSV-1 34.5 binds both the protein phosphatase 1
(PP1) and eIF2, thus facilitating eIF2 dephosphorylation and
active translation (14, 15). In the current study, we set out to
analyze the function ofHSV-1 34.5 in order to better understand
the molecular requirements for NEDA.
MATERIALS AND METHODS
Cells, viruses, and antibodies. The BMA3.1A7 macrophage cell line was
derived from C56/BL6 mice as described previously (16). BMA3.1A7,
BHK-21 (ATCC CCL-10), MEF (provided by Gilbert Arthur, University
of Manitoba, Canada), HeLa (ATCC CCL-2), Vero (ATCC CCL-81),
Vero-gH CR1 (kindly provided by Tony Minson and Helena Browne,
University of Cambridge, United Kingdom) (17, 18), Vero-ICP4 E5 (19),
and MeWo (ATCC HTB-65, kindly provided by Bruce Banfield, Queens
University, Kingston, Canada) were cultured in Dulbecco’s modified Ea-
Received 22 October 2012 Accepted 22 January 2013
Published ahead of print 30 January 2013
Address correspondence to Michel Desjardins, michel.desjardins@umontreal.ca.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.02974-12
3990 jvi.asm.org Journal of Virology p. 3990–3997 April 2013 Volume 87 Number 7
gle’s medium (DMEM) containing 10% (vol/vol) fetal calf serum (FCS)
and 2 mM glutamine.
The HSV-1 17 34.5 and HSV-1 17 beclin-1 (aa68-87) vi-
ruses have been previously described (12, 13, 20, 21). The HSV-1 17
PP1 virus that carries Val178Glu and Phe180Leu substitutions was
constructed by amplifying nucleotides 463 to 1088 ofHSV-1 by PCR from
wild-type (wt) strain 17syn infectious DNA with primers 5=-CAGACC
ACCAGGTGGCGCACCCGGACGTGGGGCGATAAGCGCTCCCGCG
CGGGGGTC-3= and 5=-GCACATGCTTGCCTGTCAAACTCT-3=. The
amplified PCR fragment with nucleotide changes (underlined) was in-
serted into pCR-BluntII-TOPO (Invitrogen, Carlsbad, CA), resulting in
pDA14, which was sequenced to verify that the plasmid contained the
desiredmutations. A 477-bp PflMI/BstEII fragment of pDA14 containing
two nucleotide changes was ligated into PflMI/BstEII-digested pDA04,
generating pDA13. pDA13 was cotransfected into Vero cells with infec-
tious viral DNA from HSV-1 strain 17syn using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Viruses from this transfection were plaque
purified and screened for incorporation of the nucleotide substitution by
PCR using the following primers: 5=-GCACATGCTTGCCTGTCAAACT
CT-3= and 5=-TGTAACGTTAGACCGAGTTCGCCG-3=. These primers
generate a PCR product that spans the mutation, which generates an AfeI
site. Wild-type and PP1 templates generate 808-bp PCR products. Fol-
lowing digestion with AfeI, PP1 PCR products were cut into 588- and
216-bp fragments, but wild-type DNA was uncut. Plaques containing the
AfeI restriction site were plaque purified three times prior to isolation of
viral DNA and Southern blot analysis that was performed as previously
described (22). Following DNA digestion of viral stocks with AfeI, an
812-bp BspEI/NcoI fragment corresponding to nucleotides 511 to 1323 of
the HSV-1 genome was labeled with 32P-dCTP by random priming. This
fragment was used as a probe to confirm the presence of the PP1 binding
mutation (data not shown). HSV-1 17wt was kindly provided by Beate
Sodeik (Medizinische Hochschule Hannover, Germany). HSV-1 stocks
were propagated in BHK-21, and titers were determined on Vero cells as
previously described (23, 24).
The following primary antibodieswere used to detect cellular proteins:
rabbit polyclonal antibody to cleaved LC3a (AP1805a; Abgent), rabbit
polyclonal to cleaved LC3b (AP1806a; Abgent), mouse monoclonal anti-
body against total LC3 (M115-3; MBL), rabbit monoclonal anti-P-eIF2
antibody (D9G8; Cell Signaling),mousemonoclonal anti-eIF2 antibody
(L57A5; Cell Signaling), mouse monoclonal anti-nuclear pore complex/
p62 antibody (MAb414; Covance),mousemonoclonal anti--tubulin an-
tibody (GTU-88; Sigma), and rabbit polyclonal anti-calnexin antibody
(kindly provided by John Bergeron, McGill University, Montreal, Can-
ada). Viral proteins were detected with a rabbit polyclonal anti-HSV-1
antibody (RB-1425-A; Neomarkers), rabbit polyclonal anti-HSV-1 VP5
antibody (H1.4; Acris), rabbit polyclonal anti-HSV-1 34.5 antibody (25)
(kindly provided by IanMohr, NewYorkUniversity), mousemonoclonal
anti-HSV-1 gH antibody (BBH1; Abcam), mouse monoclonal anti-
HSV-1 gC antibody (MBS609783; Virussys), mouse monoclonal anti-
HSV-1/2 gB antibody (M612449; Fitzgerald), mouse monoclonal
anti-HSV-1/2 gB antibody (clone 10B7, ab6506; Abcam), mouse mono-
clonal anti-HSV-1/2 ICP27 antibody (10-H44; Fitzgerald), mousemono-
clonal anti-HSV-1 ICP0 antibody (clone 5H7, ab6513; Abcam), mouse
monoclonal anti-HSV-1 ICP4 antibody (clone 10F1, ab6514; Abcam),
and rabbit polyclonal anti-HSV-1 pUL36 147 antibody (26) (kindly pro-
vided by Ari Helenius, ETH Zürich, Switzerland, and Beate Sodeik, Me-
dizinische Hochschule Hannover, Germany).
Infection and drug treatment. Cells were inoculated at a multiplicity
of infection (MOI) of 5 on a rocking platform at 37°C for 30 min. The
inoculumwas aspirated and replaced by cell culturemedium, and infected
cells were incubated until 8 h postinfection (hpi) unless indicated other-
wise. Cycloheximide and acyclovir were purchased from Sigma-Aldrich
(Oakville, Canada) and added directly after inoculation for 8 h at final
concentrations of 0.5 mM and 200 to 400 M, respectively. The transla-
tion inhibitor hippuristanol (27, 28)was kindly provided by Jerry Pelletier
(McGill University, Montreal, Canada), used at a 1 M final concentra-
tion, and added for the times indicated.
Immunofluorescence and FACS labeling. For immunofluorescence
analysis and fluorescence-activated cell sorting (FACS) labeling of intra-
cellular antigens, cells were fixed and permeabilized with the Cytofix/
Cytoperm kit according to the manufacturer’s instructions (BD Biosci-
ences, Mississauga, Canada). Proteins of interest were labeled with
primary antibodies and the corresponding secondary antibodies coupled
to Alexa 488, Alexa 568, or Alexa 647 (Invitrogen, Carlsbad). Cells were
then either analyzed by flow cytometrywith a FACSCalibur (BectonDick-
inson, Mississauga, Canada) or embedded with ProLong Gold antifade
reagent (Invitrogen, Carlsbad) and analyzed with a TCS confocal laser-
scanning microscope (Leica Microsystems, Concord, Canada). Flow cy-
tometry data were analyzed with FlowJo 8.7. Contrast adjustments of
immunofluorescence imageswere performed equally for all imageswithin
each experiment with Adobe Photoshop CS3.
Electron microscopy. For morphological analysis, infected cells were
fixed in 2.5% (vol/vol) glutaraldehyde (Canemco), embedded in Epon
(Mecalab), and thin sectioned as described previously (29). For immuno-
gold labeling, cells were fixed in 1% (vol/vol) glutaraldehyde and embed-
ded at20°C in Lowicryl (Canemco). Thin sections were incubated over-
night with the polyclonal anti-LC3a antibody at a dilution of 1:10 and for
1 h with protein A-gold.
SDS-PAGE and immunoblot assay. Protein samples were separated
by linear 4 to 15% SDS-PAGE (Bio-Rad) and transferred onto nitrocellu-
lose membrane (Pall Corporation). Proteins of interest were detected us-
ing the primary antibodies described above, followed by secondary anti-
bodies coupled to horseradish peroxidase (Jackson ImmunoResearch,
West Grove, PA) for enhanced chemiluminescence (ECL) detection
(PerkinElmer, Waltham, MA). If required, membranes were stripped by
incubation with 2% SDS, 100 mM -mercaptoethanol, and 50 mM Tris
(pH 6.8) at 56°C for 15 min and reprobed with other antibodies.
RESULTS
NEDA is a generalmechanismduringHSV-1 infection.NEDA is
a novel form of autophagy triggered during HSV-1 infection in
mouse macrophages (13). Here, we show that this process is trig-
gered in multiple cell types, including human cells, during HSV-1
infection (Fig. 1A). Immunofluorescence analyses with the au-
tophagosome marker LC3b clearly show the accumulation of this
protein on the nuclear envelope, the hallmark of NEDA, and its
colocalization with the nuclear pore complex protein p62. Unin-
fected cells show no accumulation of LC3b around the nucleus
(Fig. 1B). Electron microscopy provides direct evidence that
NEDA generates 4-membrane-layered autophagosomes from the
coiling of the nuclear envelope in all cell types analyzed (Fig. 1C).
This autophagic process results in the sequestration of cytoplas-
mic components, and viral particles are often observed inside re-
sulting vesicles. We conclude that NEDA is a general response to
HSV-1 infection in macrophages, fibroblasts, and epithelial cells
of human as well as rodent origin.
LC3a is detected on NEDA but not macroautophagosomes.
So far, no exclusive marker associated with NEDA has been iden-
tified, hindering a more thorough characterization of the molec-
ular mechanisms regulating it. As LC3b is a marker of both mac-
roautophagy and NEDA (13), we sought to verify whether an
isoform of this protein, LC3a, might also label autophagosomes
and/or the nuclear membrane during NEDA. Accordingly, we
performed immunofluorescence analyses to localize LC3a and
LC3b in cells infected with wtHSV-1 where bothNEDA andmac-
roautophagy can occur or with HSV-1 lacking 34.5 (the HSV-1
34.5 virus) to induce macroautophagy only. In HSV-1 wt-in-
fected cells, both LC3a and LC3b colocalized with gB, a viral pro-
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tein present on the nuclear envelope (Fig. 2A, closed arrowheads).
In contrast, upon infection with the HSV-1 34.5 virus, only
LC3b-positive cytoplasmic punctae were detected (Fig. 2A, bot-
tom). Therewere nodiscernible LC3a-positive structures and very
little LC3a on the nuclear envelope (Fig. 2B). The nuclear mem-
brane was formally identified by labeling with the nuclear pore
complex protein p62, which localized very closely to LC3a in
about 80% of wt HSV-1-infected cells but not in uninfected cells
(Fig. 2C,D). Immunogold labeling and electronmicroscopy dem-
onstrated that LC3a localized to the 4-membrane-bound vesicles
that are characteristic of NEDA (Fig. 2E). These data indicate that
LC3a can be used to monitor the occurrence of NEDA during
HSV-1 infection and that LC3a does not occur onmacroautopha-
gosomes. To facilitate the detection of NEDA and quantify its
occurrence, we then went on to develop a flow cytometric assay
based on themeasurement of the fluorescent signal for LC3a. (Fig.
2F). Establishing LC3a as ameans to distinguishNEDA frommac-
roautophagy allowed us to initiate the characterization of this
pathway in more detail and address the particular role played by
the viral protein 34.5 in its initiation.
NEDA requires the PP1-binding domain of 34.5 but not
the beclin-1-bindingdomain.Wehave shown that the expression
of the viral protein 34.5 during HSV-1 infection is required for
NEDA to occur (13), suggesting that this autophagic process is
engaged in response to a specific effect of 34.5 on the host cell.
This viral protein interferes with at least two distinct host defense
mechanisms. First, it partially inhibits macroautophagy by bind-
ing beclin-1 through its beclin-1-binding domain (12, 20). Thus,
NEDA could be an alternative autophagic process triggered to
counteract the inhibition of macroautophagy. Second, 34.5 also
binds and bridges two host proteins, PP1 and eIF2, that are part
of the machinery involved in shutting off protein translation in
response to HSV-1 infection (15). Binding of these proteins by
34.5 interferes with the ability of infected cells to shut off protein
translation. Thus, we hypothesized that infected cells could re-
spond with NEDA when 34.5 prevents shutoff of protein trans-
lation. To determine whether NEDA is caused as a response to the
effect of 34.5 onmacroautophagy and/or protein translation, we
used twomutant viruses displaying specificmutations in the34.5
protein. The first one lacks the beclin-1-binding domain (the
beclin-1 virus) (12, 13, 20, 21), while the second one contains
two point mutations interfering with PP1 binding (the PP1
virus) (Fig. 3A). These two point mutations were sufficient to
increase the phosphorylation of eIF2 (eIF2-P) to levels similar
to those observed with a mutant virus lacking the complete 34.5
FIG1 NEDA is triggered byHSV-1 in different cell types. BMA,HeLa,MeWo,
MEF, and BHK-21 cells were infected with HSV-1 wt at a multiplicity of in-
fection (MOI) of 5 for 8 h (A) or mock infected (B), and NEDA onset was
analyzed by labeling with antibodies against cleaved LC3b and colocalization
with the nuclear pore marker p62 (NPC). (C) HSV-1 wt-infected cells were
also analyzed by electron microscopy. Scale bar, 500 nm. White lines denote
outlines of cells as observed in transilluminated images in this and the follow-
ing figures.
FIG 2 LC3a localizes to NEDA but not macroautophagosomes. (A) Immu-
nofluorescence analysis of BMA cells infected with the HSV-1 wt or 34.5
virus,MOI 5, 8 hpi. Antibodies against both forms of LC3 labeled a perinuclear
rim (closed arrowheads) in the presence but not in the absence of 34.5. The
antibody against cleaved LC3b also labeled punctae in the cytosol in the ab-
sence of 34.5 (open arrowheads). (B) LC3a colocalization with the nuclear
envelope in mock-infected cells or cells infected with the HSV-1 wt or 34.5
virus. Quantification of three immunofluorescence experiments, 150 cells per
condition. Error bars, standard deviations (SD); ***, P 0.001 in a two-sided
Student t test. (C) Immunofluorescence of cells infected with HSV-1 wt, MOI
5, 8 hpi. Nuclear pore complexes (NPC) were labeled with an antibody against
p62, and LC3was detectedwith isoform-specific antibodies against the cleaved
forms of LC3b and LC3a. (D) Quantification of immunofluorescence data
with HSV-1 wt-infected and mock-infected cells. About 100 cells for each
condition were evaluated; error bars, SD. (E) Immunogold labeling and elec-
tron microscopy confirmed the presence of LC3a on four membrane-bound
vesicles in HSV-1 wt-infected cells. Scale bar, 250 nm. (F) Flow cytometry
analysis of LC3a labeling intensity in BMA cells infected with the HSV-1 wt or
34.5 virus or in uninfected cells.
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protein (Fig. 3B), indicating that this mutant is appropriate to
study the effect of translation on NEDA.
A strong signal for LC3a on the nuclear envelope, indicative of
NEDA, was observed in about 75% of cells infected either with the
HSV-1 wt or HSV-1 beclin-1 virus (Fig. 3C and D), suggesting
that the inhibition of macroautophagy through the binding of
34.5 to beclin is not required for the occurrence of NEDA. In
contrast, no significant recruitment of LC3a to the nuclear mem-
brane was observed in cells infected with the HSV-1 34.5 and
HSV-1 PP1 viruses. Similar results were obtained when ob-
serving LC3b localization to the nuclear envelope (data not
shown). Quantitative reverse transcription (RT)-PCR demon-
strated that the expression of LC3a and LC3b was not altered by
these viruses (data not shown). The accumulation of cleaved LC3a
after infection with the HSV-1 wt and HSV-1 beclin-1 viruses,
but not with the 34.5 and PP1 viruses, was confirmed with
the LC3a-specific flow cytometric assay (Fig. 3E). Due to accumu-
lation of LC3a in cytosolic clusters in some cells infected with the
HSV-134.5 virus but not theHSV-1PP1 virus (not shown),
overall LC3a signals appeared slightly higher with the HSV-1
34.5 virus in the flow cytometry assay. Together, these results
strongly suggest that the occurrence of NEDA is linked to elevated
levels of eIF phosphorylation, which in turn is known to regulate
translation of both viral and cellular proteins.
NEDA induction requires protein translation. To further in-
vestigate whether NEDA is engaged during changes in protein
translation, we used a pharmacological approach to alter host and
viral protein translation at various times after HSV-1 infection. A
detailed kinetic study indicated that NEDA is first observed some-
time between 5 and 6 hpi in HSV-1-infected macrophages
(Fig. 4A). Therefore, we focused on that window of time and in-
hibited protein translation at 5 hpi by treating cells with hip-
puristanol, a compound isolated from corals that interferes
strongly and very rapidly with translation by inhibiting eukaryotic
initiation factor 4 (28). Remarkably, while hippuristanol treat-
ment inhibited the recruitment of LC3a to the nuclear membrane
FIG 3 The PP1 but not the beclin-1-binding domain of 34.5 is required for NEDA. (A) HSV-1 34.5 mutants. The 34.5 protein contains a beclin-1-binding
domain (amino acids [aa] 68 to 87), a PP1 binding domain (aa 175 to 188), and an eIF2 binding domain (aa 233 to 248). Aa 68 to 87 are deleted in the HSV-1
beclin-1 virus, and in the HSV-1 PP1 virus, two point mutations inhibit PP1 binding. (B to E) BMA cells were infected with the HSV-1 wt, 34.5,
beclin-1, or PP1 virus for 8 h at an MOI of 5. (B) Immunoblot analysis with antibodies against total eIF2 and phosphorylated eIF2 (eIF2-P). (C)
Immunofluorescence with an antibody against cleaved LC3a. (D) Quantification of the number of cells in which LC3a colocalized with the nuclear envelope in
immunofluorescence. About 150 cells per condition in three experiments. Error bars, SD; ***,P 0.001 in a two-sided Student t test. (E) Flow cytometry analysis
of LC3a labeling intensity in cells infected with the four viruses.
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when added between 5 to 6 hpi, this drug had no effect on the
nuclear localization of this protein when added at 7 to 8 hpi (Fig.
4B and C). These results indicate that proteins translated between
5 to 6 hpi are required to induce NEDA and that continuous
translation is not needed to maintain the pathway once induced.
Inhibition of late viral protein production interferes with
NEDA induction, even in thepresenceof34.5. In thewindowof
time between 5 to 6 h ofHSV-1 infection, the cell producesmostly
viral proteins. Therefore, we wanted to know whether NEDA oc-
currence was linked to translation of viral proteins. HSV-1 pro-
teins are produced in three waves (30). Proteins referred to as
immediate early proteins are the first proteins expressed during
infection. These proteins initiate the production of the next wave
of so-called early proteins (31, 32). After viral DNA replication has
been initiated, the third and largest wave of viral protein produc-
tion ensues. These late proteins aremostly structural and allow the
production of progeny viral particles. However, this separation in
three groups is not absolute. Some late proteins, referred to as
leaky late, are produced in small quantities already prior to DNA
replication, and their production increases later on (31). Other
so-called true late proteins are produced only after the onset of
viral DNA replication.
Considering that NEDA is triggered between 5 and 6 hpi, we
wanted to determine whether this window of time corresponded
to the production of a given group of viral proteins. In our system,
immediate early and leaky late viral proteins were already pro-
duced prior to 5 hpi with wt HSV-1 (Fig. 5A). The production of
true late proteins took place at 5 to 6 hpi, the precise time at which
NEDAoccurred. These analyses led us to propose that the produc-
tion of true late viral proteins is required to induce NEDA. This
hypothesis was supported by the finding that cells infected with
the HSV-1 34.5 and PP1 viruses that do not trigger NEDA
also did not produce the true late viral proteins pUL36 and gC
(Fig. 5B). Furthermore, cells infected with wt HSV-1 and treated
with acyclovir, an inhibitor of DNA replication (33), did not pro-
duce true late viral proteins and displayed a dose-dependent re-
duction in NEDA (Fig. 5C to E). Under these conditions, both
FIG 4 NEDA is triggered in response to translation in between 5 to 6 h of
infection. (A) Cells infected with HSV-1 wt for 4 to 8 h or the HSV-1 PP1
virus for 8 h were analyzed for LC3a signal intensity by flow cytometry. Mock-
infected and HSV-1 PP1 virus-infected cells served as negative controls. (B
and C) Macrophages were infected with HSV-1 wt and treated with dimethyl
sulfoxide (DMSO, control) or 1 M hippuristanol (hipp) for 1 h. NEDA in-
duction was analyzed at 6 or 8 hpi in immunofluorescence with an antibody
against LC3a. The occurrence of an LC3a nuclear rimwas analyzed in about 50
cells per condition. Error bars, SD.
FIG 5 NEDA is triggered in response to true late viral protein expression. (A)
Viral protein expression kinetics inmacrophages infected with HSV-1 wt for 2
to 8 h or mock-infected cells, with antibodies for the immediate early proteins
(IE) ICP0 and ICP27, the leaky late (LL) protein 34.5, and the true late (TL)
proteins gC and pUL36. Tubulin was used as a loading control. (B) Immuno-
blot analysis of macrophages infected with the HSV-1 wt, 34.5, beclin-1,
or PP1 virus, using a polyclonal anti-HSV-1 antibody and antibodies for
VP5, 34.5, gC, and pUL36. Calnexin and tubulin were used as loading con-
trols. (C to E) Macrophages were infected with HSV-1 wt and treated with
DMSO, cycloheximide (CH), or 200 to 400Macyclovir at 0 hpi and analyzed
at 8 hpi. (C) Immunoblot with antibodies against ICP0, ICP27, 34.5, pUL36,
gC, calnexin (clxn), and LC3 (LC3-I uncleaved, LC3-II cleaved membrane-
associated form). (D and E) Immunofluorescence analysis with an antibody
against cleaved LC3a. Error bars, SD; ***, P 0.001 in a two-sided Student t
test.
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34.5 and LC3 were present. We conclude that NEDA is triggered
as a response to true late viral protein expression.
Expressionof one true late viral protein rescuesNEDA.Next,
wewanted to know ifNEDA could be induced by expressing a true
late protein in cells infected with a virus that otherwise fails to
induce NEDA. To this end, we used Vero-gH (CR1) cells, which
express the true late HSV-1 protein gH under the control of the
promoter of an early-late HSV-1 protein, and thus only when
infected with the virus (17, 18). Interestingly, the PP1 virus
inducedNEDA inVero-gH cells but not in control Vero cells or in
a Vero cell line expressing the immediate early protein ICP4
(Vero-ICP4, E5) (Fig. 6A). The level of gH expression in Vero-gH
cells infected with the PP1 virus was similar to that during
HSV-1 wt infection of control Vero cells (Fig. 6B). Quantification
of NEDA in the three different Vero cell lines demonstrated that
the occurrence of this autophagic pathway in the HSV-1 PP1
virus-infected Vero-gH cells was similar to that observed during
infection of any Vero cell line with the wt virus (Fig. 6C). This
complete rescue of the phenotype can likely be attributed to the
presence of the true late protein gH, since the expression levels of
other late viral proteins did not differ between the three Vero cell
lines (Fig. 6D). These results support our hypothesis that expres-
sion of true late viral proteins is required for NEDA and point to a
possible function of gH in this pathway.
DISCUSSION
NEDA is a cellular process induced inmacrophages duringHSV-1
infection. It differs from any of the known autophagic pathways
by the use of the inner and outer nuclear membranes as the main
source of material for the formation of 4-membrane-layered au-
tophagic structures. Although these structures display LC3b, the
hallmark marker of macroautophagosomes, we discovered that
the related protein LC3a is recruited to the nuclear envelope but
not macroautophagosomes during infection. This characteristic
allowed us to develop a FACS-based assay to measure the occur-
rence of NEDA in various conditions. Using this assay and immu-
nofluorescence microscopy, we were able to show that NEDA is
triggered in a variety of cell types during HSV-1 infection, includ-
ing human cells. These results clearly show that NEDA is a widely
used host response to HSV-1 infection. The molecular mecha-
nisms regulating this pathway are still poorly understood. In our
first report, we observed that the viral protein 34.5 is required for
the occurrence of NEDA, since a mutant virus deleted for this
protein could not induce this autophagic pathway (13). Since it is
known that the binding of 34.5 to beclin-1 interferes with mac-
roautophagy (12), we wanted to know whether the binding of
beclin-1 also affected NEDA. Therefore, we infectedmacrophages
with a virus mutant that lacked the 34.5 beclin-1-binding do-
main. Remarkably, this virus triggered NEDA as efficiently as the
wt virus, demonstrating that in contrast to macroautophagy,
NEDAwas not affected by beclin-1 binding. This strongly suggests
that NEDA is a beclin-1-independent pathway regulated by mo-
lecularmechanisms different than those associatedwithmacroau-
tophagy. Furthermore, it demonstrates that NEDA andmacroau-
tophagy are altered by 34.5 through different mechanisms.
In addition tomacroautophagy, 34.5 can interfere with a sec-
ond cellular response to HSV-1 infection—the shutoff of protein
translation (34). This response limits the production of viral pro-
teins and the assembly of viral particles. To interfere with this
antiviral response,HSV-134.5 recruits both eIF2 and the phos-
phatase PP1 to enable eIF2 dephosphorylation (15). In order to
investigate whether the activation of protein translation (by lifting
the shutoff response) is required to trigger NEDA, we constructed
amutant virus that could no longer bind PP1 and thus could not
interferewith host translational shutoff. Infection ofmacrophages
with this virus did not trigger NEDA. We concluded that active
protein translation was required for NEDA. To further investigate
the link between active protein translation andNEDA, we used an
approach where we infected cells withHSV-1 wt (a strong inducer
of NEDA) and inhibited protein translation by using specific
drugs. Inhibiting overall protein production with hippuristanol
lifted the ability of HSV-1 wt to trigger NEDA, further supporting
the link between protein translation and this autophagic pathway.
Furthermore, we treated infected cells with acyclovir, a drug that
FIG 6 NEDA is rescued by gH overexpression. Vero cells, Vero CR1 cells that
express the late HSV-1 protein gH (Vero-gH), or Vero E5 cells that express the
immediate early protein ICP4 (Vero-ICP4)were infectedwith theHSV-1wt or
HSV-1 PP1 virus at an MOI of 5 for 8 h. (A) Infected cells were detected
with an antibody against HSV-1 gB, and NEDAwas monitored by LC3a label-
ing.HSV-1PP1 caused an accumulation of LC3a around the nucleus (white
arrowheads) only in Vero-gH but not wt Vero or Vero-ICP4 cells. (B) Upon
HSV-1 PP1 virus infection, Vero-gH cells contained gH levels similar to
those of Vero cells infectedwithHSV-1wt. (C)Quantification of LC3a nuclear
rims in immunofluorescence experiments with the three Vero cell lines in
about 50 cells per condition; error bars, SD. (D) Immunoblot analysis of viral
protein expression in different Vero cell lines with antibodies against the im-
mediate early (IE) proteins HSV-1 ICP0, ICP4, and the true late (TL) proteins
gH, pUL36, and gC. Calnexin (clxn) served as a loading control.
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inhibits the production of late viral proteins. This treatment effec-
tively prevented the occurrence of NEDA, demonstrating that the
production of late viral proteins is required for the triggering of
this autophagic pathway. This explains why NEDA is observed
only at late times of infection.
Late viral proteins are expressed rapidly and in large amounts,
and some of them, like gH, localize to the nuclear envelope (35),
where they might exert a stress due to protein accumulation.
NEDAcould counteract such a stress by clearing proteins from the
nuclear envelope. This idea is supported by our previous finding
that gB is present in NEDA-derived autophagosomes (13).
As mentioned before, NEDA is not observed in cells infected
with thePP1mutant virus. Interestingly, expression of a single
late viral protein (gH) in these cells was sufficient to trigger NEDA
despite the host translational shutoff. This could be caused by an
accumulation of large amounts of gH and resulting stress on the
nuclear envelope. Alternatively, gH might fulfill a specific func-
tion in theNEDA pathway. This protein is known to contribute to
membrane fusion events at the nuclear envelope (36). However,
efficient fusion activity probably requires a concerted action of gH
with the viral proteins gL and gD (37). In a quantitative mass
spectrometry analysis of PP1 virus-infected cells, we could not
detect gL, while gD was expressed in smaller amounts than in
wt-infected cells (C. Bell, K. Radtke, P. Thibault, and M. Desjar-
dins, unpublished observations). Since gH expression in the con-
text ofPP1 virus infection and thuswithout gLwas sufficient to
trigger NEDA, the fusion activity of this protein might not play a
direct role in this autophagic pathway. Further experiments will
be required to understand the role of gH in NEDA, either as a
stress inducer or an active contributor to the pathway.
Macroautophagy is a cellular response triggered in stress con-
ditions. It has been shown thatHSV-1 is able to interfere in several
ways withmacroautophagy, a key antiviral host response involved
in clearing of particles from the cytosol and the presentation of
viral antigens (5, 7, 8, 11, 12, 20). Our results support a model
where in reaction to the initial impairment of macroautophagy
during HSV-1 infection, the production of high levels of viral
proteins triggers a host response characterized by the induction of
NEDA. This novel form of autophagy appears to be driven by
molecular mechanisms different than those governing macroau-
tophagy. Future research will be directed at identifying the viral
and cellular machinery of NEDA and the confirmation of the role
of NEDA in viral infection, viral protein degradation, and antigen
presentation.
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